focus -WSS

focus

author：Wikipedia 2025-09-30 18:21:12 - browse：8459

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Readout LOUD podcast: ASCO preview, a Duchenne trial failure

leisure time

WSS

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Readout Newsletter: Zepbound, Valneva's vaccine, and more

At ASCO, AstraZeneca reports strong data for breast cancer drug

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Wikipedia

focus

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Apple is now the first public company to be valued at $3 trillion

Publishing genetic code of viruses could cause disaster

Hollywood unions extend contract negotiations for actors

Medicare’s new pay boost for primary care is angering specialists

Tori Bowie and the unacceptable rates of Black maternal death

Carbon Health diabetes program, a test of data

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Intellia reports positive results for its CRISPR

Wikipedia

Experimental asthma app from Apple and Anthem shows promise

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

A letter from the executive editor: STAT UnitedHealth investigation

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Today's health inequities arise from racist U.S. history, say experts

leisure time

explore

leisure time

hotspot